ATE458479T1 - 1h-1,2,4- triazol-3- carboxamid derivate als cannabinoid-cb1 receptor liganden - Google Patents

1h-1,2,4- triazol-3- carboxamid derivate als cannabinoid-cb1 receptor liganden

Info

Publication number: ATE458479T1
Authority: AT; Austria
Prior art keywords: cannabinoid; triazole; receptor ligands; carboxamide derivatives; carboxamide
Prior art date: 2002-09-19

Application number

AT03797318T

Other languages

English (en)

Inventor

Josephus H M Lange

Cornelis G Kruse

Andrew C Mccreary

Stuivenberg Herman H Van

Original Assignee

Solvay Pharm Bv

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-09-19

Filing date

2003-09-17

Publication date

2010-03-15

2003-09-17 Application filed by Solvay Pharm Bv filed Critical Solvay Pharm Bv

2010-03-15 Application granted granted Critical

2010-03-15 Publication of ATE458479T1 publication Critical patent/ATE458479T1/de

Links

ZEWJFUNFEABPGL-UHFFFAOYSA-N 1,2,4-triazole-3-carboxamide Chemical class NC(=O)C=1N=CNN=1 ZEWJFUNFEABPGL-UHFFFAOYSA-N 0.000 title 1
239000003446 ligand Substances 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
- C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Diabetes (AREA)
Heart & Thoracic Surgery (AREA)
Psychiatry (AREA)
Cardiology (AREA)
Epidemiology (AREA)
Hematology (AREA)
Obesity (AREA)
Pain & Pain Management (AREA)
Psychology (AREA)
Ophthalmology & Optometry (AREA)
Hospice & Palliative Care (AREA)
Addiction (AREA)
Child & Adolescent Psychology (AREA)
Urology & Nephrology (AREA)
Emergency Medicine (AREA)
Endocrinology (AREA)
Vascular Medicine (AREA)
Otolaryngology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)

AT03797318T 2002-09-19 2003-09-17 1h-1,2,4- triazol-3- carboxamid derivate als cannabinoid-cb1 receptor liganden ATE458479T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP02078966		2002-09-19
PCT/EP2003/050628 WO2004026301A1 (en)	2002-09-19	2003-09-17	1h-1,2,4-triazole-3-carboxamide derivatives as cannabinoid-cb1 receptor ligands

Publications (1)

Publication Number	Publication Date
ATE458479T1 true ATE458479T1 (de)	2010-03-15

Family

ID=31970417

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT03797318T ATE458479T1 (de)	2002-09-19	2003-09-17	1h-1,2,4- triazol-3- carboxamid derivate als cannabinoid-cb1 receptor liganden

Country Status (24)

Country	Link
US (1)	US7319110B2 (de)
EP (1)	EP1542678B1 (de)
JP (1)	JP2006501275A (de)
KR (1)	KR100996828B1 (de)
CN (1)	CN1319529C (de)
AR (1)	AR041268A1 (de)
AT (1)	ATE458479T1 (de)
AU (1)	AU2003299024B2 (de)
BR (1)	BR0312020A (de)
CA (1)	CA2491394C (de)
DE (1)	DE60331444D1 (de)
DK (1)	DK1542678T3 (de)
ES (1)	ES2341540T3 (de)
HR (1)	HRP20050053A2 (de)
IL (1)	IL165611A (de)
MX (1)	MXPA05002862A (de)
NO (1)	NO20051870L (de)
PL (1)	PL375020A1 (de)
PT (1)	PT1542678E (de)
RU (1)	RU2325382C2 (de)
SI (1)	SI1542678T1 (de)
UA (1)	UA80298C2 (de)
WO (1)	WO2004026301A1 (de)
ZA (1)	ZA200500133B (de)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6897240B2 (en) *	2002-05-08	2005-05-24	The Regents Of The University Of California	Thio semicarbazone and semicarbazone inhibitors of cysteine proteases and methods of their use
MXPA05011276A (es) *	2003-04-21	2006-01-24	Daiichi Seiyaku Co	Derivado heterociclico de cinco miembros.
US7223780B2 (en) *	2003-05-19	2007-05-29	Sanofi-Aventis Deutschland Gmbh	Triazole-derivatives as blood clotting enzyme factor Xa inhibitors
EP1753413A2 (de) *	2003-10-24	2007-02-21	Solvay Pharmaceuticals GmbH	Neue medizinische anwendungen von verbindungen mit cb sb 1 /sb antagonistischer wirkung und kombinationsbehandlung mit diesen verbindungen
AU2004293013B2 (en) *	2003-11-19	2011-04-28	Metabasis Therapeutics, Inc.	Novel phosphorus-containing thyromimetics
US20060025448A1 (en)	2004-07-22	2006-02-02	Cadila Healthcare Limited	Hair growth stimulators
FR2874012B1 (fr) *	2004-08-09	2008-08-22	Sanofi Synthelabo	Derives de pyrrole, leur preparation et leur utlisation en therapeutique
ES2255834B1 (es) *	2004-09-14	2008-01-16	Laboratorios Del Dr. Esteve, S.A.	Nuevos derivados 1,2,4-triazol-3-carboxamida.
BRPI0516842A (pt) *	2004-10-01	2008-09-23	Hoffmann La Roche	compostos, processo para a sua manufatura, composições farmacêuticas que os compreendem, método para o tratamento terapêutico e/ou profilático de enfermidades que são moduladas por lxr alfa e/ou lxr beta agonistas e uso desses compostos
RU2007119315A (ru)	2004-10-25	2008-11-27	Зольвай Фармасьютиклз Гмбх (De)	Фармацевтические композиции, содержащие антагонисты каннабиноидного рецептора св1 и открыватели калиевых каналов, предназначенные для лечения сахарного диабета типа i, ожирения и связанных с ними состояний
US7494985B2 (en) *	2004-11-03	2009-02-24	Xenoport, Inc.	Acyloxyalkyl carbamate prodrugs, methods of synthesis, and use
MX2007013454A (es) *	2005-04-29	2008-01-21	Janssen Pharmaceutica Nv	Derivados de benzotriazol como antagonistas del receptor de cannabinoide.
AU2006253842A1 (en)	2005-06-02	2006-12-07	Glenmark Pharmaceuticals S.A.	Novel cannabinoid receptor ligands, pharmaceutical compositions containing them, and process for their preparation
US7923465B2 (en)	2005-06-02	2011-04-12	Glenmark Pharmaceuticals S.A.	Cannabinoid receptor ligands, pharmaceutical compositions containing them, and process for their preparation
TW200726765A (en) *	2005-06-17	2007-07-16	Bristol Myers Squibb Co	Triazolopyridine cannabinoid receptor 1 antagonists
US7632837B2 (en)	2005-06-17	2009-12-15	Bristol-Myers Squibb Company	Bicyclic heterocycles as cannabinoid-1 receptor modulators
CN101213182A (zh) *	2005-06-29	2008-07-02	阿斯利康(瑞典)有限公司	作为α7烟碱性受体调节剂的噻吩-2-甲酰胺
CA2613235A1 (en)	2005-06-30	2007-01-11	Prosidion Limited	Gpcr agonists
FR2894579B1 (fr) *	2005-12-12	2008-01-18	Sanofi Aventis Sa	Derives diaryltriazolmethylamine, leur preparation et leur application en therapeutique.
EP2081905B1 (de)	2006-07-28	2012-09-12	Boehringer Ingelheim International GmbH	Sulfonyl verbindungen als cb2 rezeptor modulatoren
WO2008033572A1 (en) *	2006-09-15	2008-03-20	Xenoport, Inc.	Acyloxyalkyl carbamate prodrugs, methods of synthesis and use
CL2008000017A1 (es)	2007-01-04	2008-08-01	Prosidion Ltd	Compuestos derivados de heterociclos de nitrogeno y oxigeno, agonistas de gpcr; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de la obesidad, diabetes, sindrome metabolico, hiperlipidemia, toleranci
AR064735A1 (es)	2007-01-04	2009-04-22	Prosidion Ltd	Agonistas de gpcr y composicion farmaceutica en base al compuesto
US20100048632A1 (en)	2007-01-04	2010-02-25	Matthew Colin Thor Fyfe	Piperidine GPCR Agonists
GB0700122D0 (en)	2007-01-04	2007-02-14	Prosidion Ltd	GPCR agonists
US20100048625A1 (en)	2007-01-04	2010-02-25	Matthew Colin Thor Fyfe	Piperidine gpcr agonists
CN101302200B (zh) *	2007-05-09	2011-04-20	上海医药工业研究院	制备n-哌啶子基-5-(4-氯苯基)-1-(2,4-二氯苯基)-4-甲基吡唑-3-甲酰胺的方法
GB0720389D0 (en)	2007-10-18	2008-11-12	Prosidion Ltd	G-Protein Coupled Receptor Agonists
GB0720390D0 (en)	2007-10-18	2007-11-28	Prosidion Ltd	G-Protein coupled receptor agonists
US8546563B2 (en)	2007-11-07	2013-10-01	Boehringer Ingelheim International Gmbh	Compounds which modulate the CB2 receptor
EP2265585B1 (de)	2008-02-21	2014-09-17	Boehringer Ingelheim International GmbH	Amin- und etherverbindungen, die den cb2-rezeptor modulieren
EP2326629B1 (de)	2008-07-10	2013-10-02	Boehringer Ingelheim International GmbH	Den cb2-rezeptor modulierende sulfonverbindungen
AP2011005674A0 (en)	2008-09-25	2011-04-30	Boehringer Ingelheim Int	Sulfonyl compounds which selectively modulate the CB2 receptor.
WO2010077836A2 (en)	2009-01-05	2010-07-08	Boehringer Ingelheim International Gmbh	Pyrrolidine compounds which modulate the cb2 receptor
WO2010079241A1 (es)	2009-01-12	2010-07-15	Fundacion Hospital Nacional De Paraplejicos Para La Investigacion Y La Integracion	Uso de antagonistas y/o agonistas inversos de los receptores cb1 para la preparación de medicamentos que incrementen la excitabilidad de las motoneuronas
WO2010096371A2 (en)	2009-02-18	2010-08-26	Boehringer Ingelheim International Gmbh	Heterocyclic compounds which modulate the cb2 receptor
US8299103B2 (en)	2009-06-15	2012-10-30	Boehringer Ingelheim International Gmbh	Compounds which selectively modulate the CB2 receptor
JP5756800B2 (ja)	2009-06-16	2015-07-29	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	Ｃｂ２受容体を調節するアゼチジン２−カルボキサミド誘導体
WO2011037795A1 (en)	2009-09-22	2011-03-31	Boehringer Ingelheim International Gmbh	Compounds which selectively modulate the cb2 receptor
US9315454B2 (en)	2010-01-15	2016-04-19	Boehringer Ingelheim International Gmbh	Compounds which modulate the CB2 receptor
US8329735B2 (en)	2010-03-05	2012-12-11	Boehringer Ingelheim International Gmbh	Tetrazole compounds which selectively modulate the CB2 receptor
WO2012012307A1 (en)	2010-07-22	2012-01-26	Boehringer Ingelheim International Gmbh	Sulfonyl compounds which modulate the cb2 rece
CN102558157B (zh) *	2010-12-20	2014-04-30	中国科学院上海药物研究所	羟乙基三唑类化合物或氨乙基三唑类化合物及其制备方法和用途
CN102731418B (zh) *	2012-07-15	2015-03-11	浙江大学	1-取代-1h-1,2,4-三氮唑-甲酰胺衍生物及其制备和用途
MX361761B (es) *	2012-09-17	2018-12-17	Hoffmann La Roche	Derivados de triazol carboxamida.
EP2803668A1 (de)	2013-05-17	2014-11-19	Boehringer Ingelheim International Gmbh	Neuartige (Cyano-dimethyl-methyl)-isoxazole und -[1,3,4]-thiadiazole
CA2949559C (en)	2014-06-06	2023-08-29	Research Triangle Institute	Apelin receptor (apj) agonists and uses thereof
CA2975474C (en)	2015-01-30	2023-06-13	Neurocrine Biosciences, Inc.	Substituted triazoles and methods relating thereto
MA43417A (fr)	2015-12-09	2018-10-17	Res Triangle Inst	Agonistes améliorés du récepteur de l'apéline (apj) et leurs utilisations
CN109790151B (zh)	2016-10-12	2022-03-29	三角研究所	杂环爱帕琳肽受体(apj)激动剂及其用途
US11655238B2 (en)	2018-11-20	2023-05-23	Shanghaitech University	MMPL3 inhibitors, compositions and uses thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE3316300A1 (de) *	1982-05-07	1983-11-24	Kureha Kagaku Kogyo K.K., Tokyo	Heribizide zusammensetzung mit einem gehalt an einem derivat des 1,2,4-triazols als wirkstoff
JPS58194866A (ja) *	1982-05-07	1983-11-12	Kureha Chem Ind Co Ltd	トリアゾ−ル誘導体及び該誘導体を含有する除草剤
DE3817192A1 (de) *	1988-05-20	1989-11-30	Hoechst Ag	1,2,4-triazolderivate enthaltende pflanzenschuetzende mittel sowie neue derivate des 1,2,4-triazols
FR2692575B1 (fr) *	1992-06-23	1995-06-30	Sanofi Elf	Nouveaux derives du pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant.
DE4225778A1 (de) *	1992-08-04	1994-02-17	Hoechst Ag	1,2,4-Triazolyl-3-carbonsäure-4-aminopiperidide, Verfahren zu ihrer Herstellung, sie enthaltende Mittel und ihre Verwendung als Schädlingsbekämpfungsmittel, insbesondere Fungizide
DE4425144A1 (de) *	1994-07-15	1996-01-18	Basf Ag	Triazolverbindungen und deren Verwendung
FR2741621B1 (fr) *	1995-11-23	1998-02-13	Sanofi Sa	Nouveaux derives de pyrazole, procede pour leur preparation et compositions pharmaceutiques en contenant
FR2789079B3 (fr) *	1999-02-01	2001-03-02	Sanofi Synthelabo	Derive d'acide pyrazolecarboxylique, sa preparation, les compositions pharmaceutiques en contenant
FR2796945B1 (fr) *	1999-07-30	2002-06-28	Sod Conseils Rech Applic	Nouveaux derives d'hydantoines, de thiohydantoines, de pyrimidinediones et de thioxopyrimidinones, leurs procedes de preparation et leur application a titre de medicaments
DE60023167T2 (de)	1999-10-18	2006-06-14	Univ Connecticut Farmington	Pyrazol-derivate als cannabinoidrezeptor-antagonisten
FR2802206B1 (fr) *	1999-12-14	2005-04-22	Sod Conseils Rech Applic	Derives de 4-aminopiperidine et leur utilisation en tant que medicament
WO2001058869A2 (en)	2000-02-11	2001-08-16	Bristol-Myers Squibb Company	Cannabinoid receptor modulators, their processes of preparation, and use of cannabinoid receptor modulators in treating respiratory and non-respiratory diseases

2003
- 2003-07-19 HR HR20050053A patent/HRP20050053A2/xx not_active Application Discontinuation
- 2003-09-16 US US10/662,477 patent/US7319110B2/en not_active Expired - Fee Related
- 2003-09-16 AR ARP030103347A patent/AR041268A1/es unknown
- 2003-09-17 JP JP2004537155A patent/JP2006501275A/ja active Pending
- 2003-09-17 PL PL03375020A patent/PL375020A1/xx not_active Application Discontinuation
- 2003-09-17 AT AT03797318T patent/ATE458479T1/de active
- 2003-09-17 EP EP03797318A patent/EP1542678B1/de not_active Expired - Lifetime
- 2003-09-17 PT PT03797318T patent/PT1542678E/pt unknown
- 2003-09-17 CA CA2491394A patent/CA2491394C/en not_active Expired - Fee Related
- 2003-09-17 UA UAA200503704A patent/UA80298C2/uk unknown
- 2003-09-17 ES ES03797318T patent/ES2341540T3/es not_active Expired - Lifetime
- 2003-09-17 AU AU2003299024A patent/AU2003299024B2/en not_active Ceased
- 2003-09-17 KR KR1020057004584A patent/KR100996828B1/ko not_active Expired - Fee Related
- 2003-09-17 DK DK03797318.7T patent/DK1542678T3/da active
- 2003-09-17 DE DE60331444T patent/DE60331444D1/de not_active Expired - Lifetime
- 2003-09-17 MX MXPA05002862A patent/MXPA05002862A/es active IP Right Grant
- 2003-09-17 RU RU2005103244/04A patent/RU2325382C2/ru not_active IP Right Cessation
- 2003-09-17 CN CNB038173522A patent/CN1319529C/zh not_active Expired - Fee Related
- 2003-09-17 WO PCT/EP2003/050628 patent/WO2004026301A1/en not_active Ceased
- 2003-09-17 BR BR0312020-1A patent/BR0312020A/pt not_active IP Right Cessation
- 2003-09-17 SI SI200331803T patent/SI1542678T1/sl unknown
2004
- 2004-12-07 IL IL165611A patent/IL165611A/en not_active IP Right Cessation
2005
- 2005-01-06 ZA ZA200500133A patent/ZA200500133B/en unknown
- 2005-04-18 NO NO20051870A patent/NO20051870L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
US7319110B2 (en)	2008-01-15
AR041268A1 (es)	2005-05-11
AU2003299024A1 (en)	2004-04-08
EP1542678B1 (de)	2010-02-24
CN1319529C (zh)	2007-06-06
CA2491394A1 (en)	2004-04-01
ZA200500133B (en)	2005-11-01
US20040106614A1 (en)	2004-06-03
DK1542678T3 (da)	2010-06-07
AU2003299024B2 (en)	2008-03-06
KR100996828B1 (ko)	2010-11-29
RU2325382C2 (ru)	2008-05-27
IL165611A0 (en)	2006-01-15
IL165611A (en)	2010-04-15
EP1542678A1 (de)	2005-06-22
NO20051870L (no)	2005-06-03
MXPA05002862A (es)	2005-05-27
WO2004026301A1 (en)	2004-04-01
ES2341540T3 (es)	2010-06-22
BR0312020A (pt)	2005-03-22
CA2491394C (en)	2010-06-15
DE60331444D1 (de)	2010-04-08
HRP20050053A2 (en)	2005-04-30
SI1542678T1 (sl)	2010-07-30
CN1671377A (zh)	2005-09-21
RU2005103244A (ru)	2005-06-27
PL375020A1 (en)	2005-11-14
PT1542678E (pt)	2010-05-25
HK1078796A1 (en)	2006-03-24
KR20050057399A (ko)	2005-06-16
UA80298C2 (en)	2007-09-10
JP2006501275A (ja)	2006-01-12

Legal Events

Date

Code

Title

Description

2010-09-15

UEP

Publication of translation of european patent specification

Ref document number: 1542678

Country of ref document: EP

2011-09-15

EEFA

Change of the company name

Publication	Publication Date	Title
ATE458479T1 (de)	2010-03-15	1h-1,2,4- triazol-3- carboxamid derivate als cannabinoid-cb1 receptor liganden
ATE384053T1 (de)	2008-02-15	Triazolderivate als tachykininrezeptor- antagonisten
DK1471065T3 (da)	2008-03-25	Hidtil ukendt 1,2,4-triazolforbindelse
NO20054082D0 (no)	2005-09-02	Pyrazol`1,5-A! 1,3,5! triazinderivater som kannabinoidreseptorligander
ATE354570T1 (de)	2007-03-15	5,6-diaryl-pyrazineamidderivate als cb1 antagonisten
DE60217503D1 (de)	2007-02-22	N-phenylpyrrol guanidin derivate als melanocortinrezeptor liganden
ATE253067T1 (de)	2003-11-15	Diazabicyloderivate als nikotin-acetylcholin- rezeptorliganden
DE60225563D1 (de)	2008-04-24	4-amino-6-phenyl-pyrroloä2,3-düpyrimidin derivate
DE60020812D1 (de)	2005-07-21	Heteroaryl-substituierte chinolin-2-on derivate verwendbar als antikrebsmittel
ATE293618T1 (de)	2005-05-15	4, 5, 6, 7-tetrahydroindazolderivate als antitumormittel
ATE244236T1 (de)	2003-07-15	Substituierte azole
ATE425147T1 (de)	2009-03-15	Imidazolderivate
DE60207815D1 (de)	2006-01-12	1-aryl-oder 1-alkylsulfonylbenzazol derivate als 5-hydroxytryptamin-6 liganden
DE602004024770D1 (de)	2010-02-04	Substituierte 8-perfluoro-6,7,8,9-tetrahydropyrimido-(1,2a) pyrimidin-4-on derivate
ATE349440T1 (de)	2007-01-15	Als antikrebsmittel verwendbare heterocyklische derivate
ATE432282T1 (de)	2009-06-15	2-alkinyl- und 2-alkenyl-pyrazolo-ä4,3-eü -1,2,4- triazolo-ä1,5-cü -pyrimidinadenosin a2a rezeptorantagonisten
DE60317684D1 (de)	2008-01-03	SUBSTITUIERTE 2,4-DIHYDROPYRROLOc3,4BÜCHINOLIN-9-ONDERIVATE, DIE SICH ALS PHOSPHODIESTERASEINHIBITOREN EIGNEN
ATE377008T1 (de)	2007-11-15	Imidazolderivate als glutamatrezeptorantagonisten
NL1027084A1 (nl)	2005-03-24	Gesubstitueerde triazoolderivaten als oxytocine-antagonisten.
DE60231897D1 (de)	2009-05-20	Triazol derivate als cyclooxygenase inhibitoren
ATE308325T1 (de)	2005-11-15	Triaryl-oxy-aryloxy-pyrimidine-2,4,6-trion derivate als metalloproteinase inhibitoren
ATE325123T1 (de)	2006-06-15	Imidazoquinoline derivate als adenosine a3 rezeptor liganden
ATE338043T1 (de)	2006-09-15	5-methoxy-8-aryl- 1,2,4ötriazolo 1,5-aöpyridine derivative als adenosin-rezeptor antagonisten
ATE433956T1 (de)	2009-07-15	Cannabinoid-rezeptorliganden
ATE427945T1 (de)	2009-04-15	Imidazolderivate